Anthony Quinn, EVP, CMO & Head of R&D at SYNAGEVA BIOPHARMA CORP (GEVA), sold 10,000 shares at $105.00 ($1.1M) on 2015-04-15, disclosed to the SEC on 2015-04-17.
Scheduled sale ($1.1M) by EVP, CMO & Head of R&D under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| GEVA | SELL | 2015-04-23 | $1.1M | — | Filing → |
| GEVA | SELL | 2015-04-08 | $2.8M | — | Filing → |
| GEVA | SELL | 2014-04-03 | $1.7M | — | Filing → |